Global Gaucher Disease Market 2015-2019

www.technavio.comenquiry@technavio.com

USA – CANADA – UK – CHINA – INDIA

Global Gaucher Disease Market 2015-2019

The report discusses the following in-depth:

• Market Size and Forecast

• Market Segmentation

• Buying Criteria

• Vendor Landscape

• Business Segmentation

• Geographical Segmentation

For more information on theGlobal Gaucher Disease

Market 2015-2019,please mail us at

enquiry@technavio.com

USA – CANADA – UK – CHINA – INDIA

Key Trends

TechNavio’s Senior Analyst says, “The market is expected to witness several trends during the forecast period. One such trend is an increase in awareness among regulatory authorities. Regulatory assistance enables drug makers in developing various treatments. The regulatory bodies are also working toward developing guidelines and providing assistance to drug manufacturers to promote research in this area. Another trend in the market is an increase in public awareness.”

• Gaucher disease is a genetic disorder characterized by the accumulation of fatty substances in cells and certain organs of the body. It is caused by the deficiency of the enzyme glucocerebrosidase. This results in the accumulation of certain detrimental lipids in the body, especially the glycolipid glucocerebroside.

• TechNavio's analysts forecast the Global Gaucher Disease market to grow at a CAGR of 7.60 percent over the period 2014-2019.

• Understanding the key drivers influencing the market

• Understanding the challenges faced by the market

• Activities of various stakeholders involved

• Key focus areas for the vendors

• Major trends that will shape the future of this market

• Vendor landscape and trajectory of the market

• Conclusion

Scope of The Report

A detailed analysis of each market driver, challenge

and trend isavailable in our report:

Global Gaucher Disease Market 2015-2019

USA – CANADA – UK – CHINA – INDIA

USA – CANADA – UK – CHINA – INDIA

Vendors

To understand the vendor landscape and for a full list of vendors view our report:

Global Gaucher

Disease Market 2015-2019

Actelion Pharmaceuticals Ltd.

Genzyme Corp.

Pfizer Inc.

Actelion Pharmaceuticals Ltd offers Zavesca for the treatment of Type 1 Gaucher disease. Zavesca was approved by the FDA in 2003 for treatment of Type 1 Gaucher disease, where enzyme replacement therapy is not a suitable therapeutic option.

Genzyme was established in 1981 and is headquartered at Cambridge, Massachusetts, the US. It is a biotechnology company which engages in the R&D, manufacturing, and marketing of a wide range of drugs and pharmaceuticals. It operates as a subsidiary of Sanofi after it was acquired by the company in 2011.

Pfizer is a research-based biopharmaceutical company. The company produces, manufactures, and develops a broad range of pharmaceutical products for cardiovascular, arthritis, metabolic disorders, infectious, and respiratory therapeutic areas. The company operates and markets its products in more than 150 countries worldwide.

USA – CANADA – UK – CHINA – INDIA

Market Landscape

• The Global Gaucher Disease market is expected to grow at a moderate pace during the forecast period, driven by the unmet medical needs in the market coupled with the special provisions granted for orphan drugs.

• In addition, the ICD-10 code designation coupled with low advertising costs and growing public awareness is expected to drive the market during the forecast period.

• However, challenges such as the high cost of therapy, stringent regulatory guidelines, and a limited patient population are expected to hinder the growth of the market.

• In addition, there are no molecules in the pre-registration stage or under Phase III clinical trials.

• Most drugs under development are in the preclinical stage, which is a challenge to the growth of the market.

USA – CANADA – UK – CHINA – INDIA

Key Buying CriteriaGuest Bloggers

• Authenticity • Delivery • Price• Service

Support

Parameter Details

Affordability Drugs available at reasonable prices are preferred

Availability Drugs should be readily available to cater to the demand

Efficacy Drugs with higher efficacy will have a high demand

Safety Drugs with less side-effects are expected to be high in demand

• Growth Forecasts?

• Market Analysis?

• Revenue Forecasts?

• Regional and Country level Analysis?

• Competitive Structure?

• Emerging Trends?

• Vendor Landscape?

• Other?

What Would You Like to Learn From TechNavio?

Global Gaucher Disease Market 2015-2019

Let us identify your needs.We would love to hear more!

USA – CANADA – UK – CHINA – INDIA

Our Report Covers: Market Scenarios, Vendor landscape & Industry Road Maps.

You have the Option to Customize Reports & Access Analysts on every Report Purchase.

Purchasing this report?

For media enquiries,please drop us a mail at

media@technavio.com

We’ll include an hour with our analysts to discuss the report findings.

For free.

USA – CANADA – UK – CHINA – INDIA

Access the Report

USA – CANADA – UK – CHINA – INDIA

India: An Overview

USA – CANADA – UK – CHINA – INDIA

About Us

USA – CANADA – UK – CHINA – INDIA

Thank You!

North America

Chicago, USA

Phone: +1 630 333 9501  

Fax: +1 630 833 2171

Europe

London, United Kingdom

Phone: +44 208 123 1770

Fax: +44 845 280 2825

Asia

Bangalore, India

Phone: +91 934 254 0560

Fax: +91 80 4080 6070

DISCLAIMER

This presentation is intended solely for showcasing Infiniti’s research capabilities. All information contained within this presentation has been randomized and should not be used for any kind of analysis and/or for decision making purpose. All trademarks and copyrights remain the sole ownership of their rightful owners/licensees. In no event shall

Infiniti Research have any liability to any party for special, incidental, tort, or consequential damages arising out of or in connection with this report, even if Infiniti Research has been advised of the possibility of such damages.

Copyright ©2013 Infiniti Research Limited. All Rights Reserved.

Reproduction without written permission is completely forbidden.

NOT FOR FURTHER DISTRIBUTION